AUGX vs. NUTX, AMWL, GNTA, CKPT, CARM, GMTX, CDTX, COCH, LENZ, and NOTV
Should you be buying Augmedix stock or one of its competitors? The main competitors of Augmedix include Nutex Health (NUTX), American Well (AMWL), Genenta Science (GNTA), Checkpoint Therapeutics (CKPT), Carisma Therapeutics (CARM), Gemini Therapeutics (GMTX), Cidara Therapeutics (CDTX), Envoy Medical (COCH), LENZ Therapeutics (LENZ), and Inotiv (NOTV). These companies are all part of the "medical" sector.
Augmedix (NASDAQ:AUGX) and Nutex Health (NASDAQ:NUTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, community ranking, risk and media sentiment.
In the previous week, Augmedix had 24 more articles in the media than Nutex Health. MarketBeat recorded 25 mentions for Augmedix and 1 mentions for Nutex Health. Nutex Health's average media sentiment score of 0.00 beat Augmedix's score of -0.04 indicating that Nutex Health is being referred to more favorably in the news media.
Augmedix has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, Nutex Health has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500.
87.1% of Augmedix shares are held by institutional investors. Comparatively, 5.3% of Nutex Health shares are held by institutional investors. 11.0% of Augmedix shares are held by insiders. Comparatively, 38.5% of Nutex Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Augmedix currently has a consensus price target of $3.88, indicating a potential upside of 220.25%. Nutex Health has a consensus price target of $15.00, indicating a potential upside of 2,006.74%. Given Nutex Health's stronger consensus rating and higher probable upside, analysts plainly believe Nutex Health is more favorable than Augmedix.
Augmedix has higher earnings, but lower revenue than Nutex Health. Augmedix is trading at a lower price-to-earnings ratio than Nutex Health, indicating that it is currently the more affordable of the two stocks.
Nutex Health has a net margin of -15.85% compared to Augmedix's net margin of -41.95%. Nutex Health's return on equity of -44.06% beat Augmedix's return on equity.
Nutex Health received 2 more outperform votes than Augmedix when rated by MarketBeat users. Likewise, 100.00% of users gave Nutex Health an outperform vote while only 50.00% of users gave Augmedix an outperform vote.
Summary
Nutex Health beats Augmedix on 12 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding AUGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Augmedix Competitors List
Related Companies and Tools
